Condition: Arrhythmogenic Right Ventricular Cardiomyopathy · Sponsor: Tenaya Therapeutics
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
This description comes directly from the study's public registry record.
Matthew Pollman, MD · 650-209-8092 · mpollman@tenayathera.com
Niharika Kamat, MS · clinical.trials@tenayathera.com
Always discuss trial participation with your own doctor first.
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| University of Colorado, Denver | Aurora, Colorado, United States | Recruiting |
| John Hopkins University School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| New York University | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Hopital Louis Pradel | Bron, France | Recruiting |
| Nantes University Hospital | Nantes, France | Recruiting |
| Pitié-Salpêtrière Hospital | Paris, France | Recruiting |
| Hôpital Haut-Lévêque | Pessac, France | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06311708